Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02168270 · ClinicalTrials.gov registry record · Phase 1
Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma
A Phase 1 study, sponsored by University of Nebraska.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02168270 is a Phase 1 study that was terminated before completion, run by University of Nebraska. The registered enrollment target is 4 participants.
The verdict
NCT02168270, a Phase 1 study, was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of ascorbic acid when given together with temozolomide in treating patients with high-grade glioma that has come back. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ascorbic acid contains ingredients that may prevent or slow the growth of high-grade gliomas. Giving temozolomide with ascorbic acid may kill more tumor cells.
Interventions
- OTHER laboratory biomarker analysis
- DRUG temozolomide
- OTHER quality-of-life assessment
- DIETARY_SUPPLEMENT ascorbic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2014-06-16 |
| Est. Completion | 2015-08-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02168270
The ClinicalTrials.gov registry entry for NCT02168270 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT02168270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02168270 about?
NCT02168270 is a clinical study titled "Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma". This phase I trial studies the side effects and best dose of ascorbic acid when given together with temozolomide in treating patients with high-grade glioma that has come back. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killi...
What is the current status of trial NCT02168270?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2014-06-16. Estimated completion is 2015-08-20.
What interventions are being tested in trial NCT02168270?
The interventions under investigation include: laboratory biomarker analysis (OTHER), temozolomide (DRUG), quality-of-life assessment (OTHER), ascorbic acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02168270?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.